Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-06
2000-10-10
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 23, 514 54, A61K 3170
Patent
active
061302058
ABSTRACT:
A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le.sup.a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, as well as a method for diagnosing secretors and nonsecretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells, vaginal secretions or buccal epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and a method for diagnosing secretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells or vaginal secretions for the presence or absence of at least one of globo H, globo ABO and lacto ABO, and detecting for the presence or absence of the at least one of globo H, globo ABO and lacto ABO and, further, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue, and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue.
REFERENCES:
patent: 5011920 (1991-04-01), Hakomori et al.
patent: 5118804 (1992-06-01), Defaye et al.
patent: 5168043 (1992-12-01), Cordon-Cardo et al.
patent: 5173292 (1992-12-01), Schrump et al.
patent: 5272138 (1993-12-01), Hakomori et al.
patent: 5281702 (1994-01-01), Tubaro et al.
Henrik, Clausen et al., "Novel Blood Group H Glycolipid Antigens Exclusively Expressed in Blood Group A and AB Erythrocytes", J of Biological Chemistry, vol. 261, No. 3, pp. 1388-1392, Jan. 1986.
Clausen, Henrik et al., "Blood Group A Glycolipid ( A.sup.x) with Globo-Series Structure", Biochem and Biophysical Research Comm, vol. 124, No. 2, pp. 523-529, Oct. 30, 1984.
Forni, Luciana, "Reagents for Immunoflourescence and Their Use for Studying Lymphoid Cell Products", Immunological Methods, Academic Press, New York, pp. 151-167, 1979.
Hafland, Peter et al., "Immunochemistry of the Lewis-Blood-Group System Partial Characterization", Archives of Biochemistry and Biophysics, vol. 210, No. 1, pp. 383-395, 1981.
Scheithauer, R., "ABO-Blutgruppenpragung an weiblichen Genitalorganen", Z Rechtsmed, vol. 100, pp. 149-156, 1988.
Schoolnik, Gary K., "How Escherichia Coli Infects the Urinary Tract", The New England Journal of Medicine, vol. 320, No. 12, p. 804-805, Mar. 1989.
Rahat, A. et al., "Semi-Quantitative Determination of H Type 1 and Type 2 Antigens on Buccal Epithelial Cells", Vox Sanguinis, vol. 59, pp. 101-105, 1990.
Zhou, Bin et al., "The Rapid Determination of the ABO Group from Body Fluids (or Stains) by Dot Enzyme-Linked Immunosorbent Assay", Journal of Forensic Sciences, vol. 35, No. 5, pp. 1125-1132, Sep. 1990.
Stapleton et al., "Binding of Uropathogenic . . . Group Antigens", Clinical Research, vol. 39, No. 2, May 1991.
pap-2-Encoded Fimbriae Adhere to the P Blood Group-Related Glycosphingolipid Stage-Specific Embryonic Antigen 4 in Human Kidney, Joan F. Karr et al., Infection and Immunity, Dec. 1990, p. 4055-4062.
"Chemical identification . . . human erythrocytes", Leffler & Eden FEMS Micro. Lett. 1980, 8; p. 127-134.
"The receptor repertoire . . . recognize Globo-A" Lindstedt et al., Infec. Imm. Mar. 1991, 59(3) p. 1086-1092.
"Binding of uropathogenic . . . secretor status", Stapleton et al., J. Clin. Invest. Sep. 1992, 90: p. 965-972.
"Binding of uropathogenic . . . group antigens", Stapleton et al., Clin, Res. Apr. 1991, 39(2).
"Association of the . . . in women", Sheinfeld et al., N.E.J.M. Mar. 1989, 320(12) p. 773-777.
"Glycolipid receptors . . . and Age", Leffler et al., in "Host Parasite . . . Tract Infections" 1989 Univ. of Chicago Press.
Hakomori Sen-itiroh
Nudelman Edward
Stamm Walter E.
Stapleton Ann
Stroud Mark
Peselev Elli
The Biomembrane Institute
The Regents of the University of Washington
LandOfFree
Method for determining susceptibility to Escherichia coli urinar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining susceptibility to Escherichia coli urinar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining susceptibility to Escherichia coli urinar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257085